SYS | | c019047 |
LBL | | ^^^^^nam^^22^^^^^^^^450^ |
005 | | 20010517152043.0 |
100 | | $a 19970611d1997 u y0sloc0103 ba |
101 | 0- | $a eng |
102 | | $a US |
105 | | $a y z 100yy |
200 | 1- | $a 3rd Dahl international symposium on genetic and salt hypertension $f edit. Louis Tobian, Junichi Iawai |
210 | | $a New York $c Elsevier Science $d 1997 |
215 | | $a s. 28-126 |
225 | 2- | $a American Journal of Hypertension $v Suppl. $x 0895-7061 |
541 | 1- | $a 3. Dahlove medzinárodné sympózium o genetike a hypertenzii spôsobenej soľou $z slo |
606 | | $a hypertenzia $x diagnostika $x prevencia a kontrola $2 mesh $3 sllk_un_auth*d006973 |
606 | | $3 sllk_un_auth*d003226 $a kongresy ako téma $2 mesh |
606 | | $a choroby kardiovaskulárne $2 mesh $3 sllk_un_auth*d002318 |
606 | | $a tlak krvný $2 mesh $3 sllk_un_auth*d001794 |
606 | | $a nádory žalúdka $x komplikácie $2 mesh $3 sllk_un_auth*d013274 |
606 | | $a hypertrofia $2 mesh $3 sllk_un_auth*d006984 |
606 | | $a osteoporóza $x diagnostika $x terapia $2 mesh $3 sllk_un_auth*d010024 |
606 | | $a epidemiológia $2 mesh $3 sllk_un_auth*d004813 |
606 | | $a hypertenzia $x komplikácie $2 mesh $3 sllk_un_auth*d006973 |
606 | | $a systém renín-angiotenzín $2 mesh $3 sllk_un_auth*d012084 |
606 | | $a obezita $x metabolizmus $2 mesh $3 sllk_un_auth*d009765 |
606 | | $a frekvencia srdcová $2 mesh $3 sllk_un_auth*d006339 |
606 | | $a soli $2 mesh $3 sllk_un_auth*d012492 |
606 | | $3 sllk_un_auth*d007668 $a oblička $x trendy $2 mesh |
606 | | $a kalikreíny $2 mesh $3 sllk_un_auth*d007610 |
606 | | $a genetika $x diagnostika $2 mesh $3 sllk_un_auth*d005823 |
606 | | $3 sllk_un_auth*d005923 $a glomeruloskleróza fokálna segmentálna $2 mesh |
606 | | $3 sllk_un_auth*d006949 $a hyperlipidémie $2 mesh |
675 | | $a 616.12-008.331.1:001.891 $v 1. stred. $z slo |
702 | -1 | $a Tobian $b Louis $3 sllk_un_auth*p0004608 $4 340 |
702 | -1 | $a Iawai $b Junichi $3 sllk_un_auth*p0004609 $4 340 |
801 | -0 | $a SK $b BA006 $c 19981223 $g AACR2 |